Literature DB >> 19885582

Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas.

Katarzyna Szczuraszek1, Verena Materna, Agnieszka Halon, Grzegorz Mazur, Tomasz Wróbel, Kazimierz Kuliczkowski, Adam Maciejczyk, Maciej Zabel, Marcin Drag, Manfred Dietel, Hermann Lage, Pawel Surowiak.   

Abstract

One of the leading causes of chemotherapy failure in non-Hodgkin's lymphomas (NHLs) is multidrug resistance (MDR). MDR can be associated with expression of members of the family of ABC-transporters. Since a correlation between expression of cyclooxygenase-2 (COX-2) and MDR in various cancer cells was described, the expression of COX-2 and the ABC-transporters MDR1/P-glycoprotein (P-gp), MRP1, MRP2 and BCRP was examined in 56 previously non-treated patients by immunohistochemistry. The data show that: i) P-gp is not expressed in non-treated NHLs; ii) MRP2 can be localized in the nuclear membranes of NHL cells; iii) expression of MRP2 in the cytoplasm membrane correlates with clinical response; iv) elevated expression of BCRP is typical for the patients, who did not respond to primary chemotherapy and for cases with shorter progression-free survival time in a 30 months follow-up; and v) there is a strong correlation between COX-2 and MRP1, MRP2 and BCRP. It can be concluded that: i) BCRP may be a crucial factor involved in primary resistance of NHLs, thus it may be useful for prediction of chemotherapeutic treatment and risk of relapse; and ii) since there is strong correlation between COX-2 expression and MDR in NHLs, the application of COX-2 inhibitors may be considered for chemosensitization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885582     DOI: 10.3892/or_00000570

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.

Authors:  Yuan Yuan; Zhulin Yang; Xiongying Miao; Daiqiang Li; Ziru Liu; Qiong Zou
Journal:  Tumour Biol       Date:  2015-07-16

2.  A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.

Authors:  Daniele Campa; Katja Butterbach; Susan L Slager; Christine F Skibola; Silvia de Sanjosé; Yolanda Benavente; Nikolaus Becker; Lenka Foretova; Marc Maynadie; Pierluigi Cocco; Anthony Staines; Rudolf Kaaks; Paolo Boffetta; Paul Brennan; Lucia Conde; Paige M Bracci; Neil E Caporaso; Sara S Strom; Nicola J Camp; James R Cerhan; Federico Canzian; Alexandra Nieters
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

3.  ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome.

Authors:  Adam Maciejczyk; Ewa Jagoda; Teresa Wysocka; Rafał Matkowski; Balázs Györffy; Hermann Lage; Paweł Surowiak
Journal:  Pathol Oncol Res       Date:  2011-10-11       Impact factor: 3.201

4.  Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.

Authors:  Nasser K Altorki; Paul Christos; Jeff L Port; Paul C Lee; Farooq Mirza; Cathy Spinelli; Roger Keresztes; Debra Beneck; Subroto Paul; Brendon M Stiles; Yuwei Zhang; David S Schrump
Journal:  J Thorac Oncol       Date:  2011-06       Impact factor: 15.609

5.  Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Authors:  Lucia Hiľovská; Rastislav Jendželovský; Peter Fedoročko
Journal:  Mol Clin Oncol       Date:  2014-10-16

6.  The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.

Authors:  Jennifer N Dulin; Meredith L Moore; Raymond J Grill
Journal:  J Neurotrauma       Date:  2013-01-23       Impact factor: 5.269

Review 7.  Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.

Authors:  Yi-Jun Wang; Yun-Kai Zhang; Rishil J Kathawala; Zhe-Sheng Chen
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.